ANAPTYSBIO - ABOUT ABOUT TECHNOLOGY PIPELINE INVESTORS / NEWS CAREERS OVERVIEW AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development of our proprietary product candidates, and where applicable, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights. Our most advanced wholly-owned antibody programs, Imsidolimab, Rosnilimab and ANB032, are designed to modulate therapeutic targets that are genetically associated with human inflammatory disorders. We are developing our imsidolimab product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis (GPP), acne and hidradenitis suppurativa. Our third wholly-owned program Rosnilimab, an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases. Our fourth wholly-owned program is an anti-BTLA modulator antibody, known as ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance. Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with GlaxoSmithKline (GSK) and inflammation-focused collaboration with Bristol-Myers Squibb (BMS). STRATEGY Advancing our lead wholly-owned programs for the treatment of severe inflammatory disease We are advancing imsidolimab, our anti-IL-36R antibody (Imsidolimab) for the treatment of generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP), EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne. We are also developing Rosnilimab, our anti-PD-1 agonist antibody program, to address to T-cell driven human inflammatory diseases, and we intend to develop ANB032, our anti-BTLA modulator antibody, in human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. Identifying emerging target biology opportunities in inflammation We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement. Expanding our proprietary pipeline by generating new antibody product candidates using our technology platform Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly-owned new therapeutic antibody program to IND submission. Retaining rights to strategic products in key commercial markets We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization. MANAGEMENT HAMZA SURIA President and CEO Hamza Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas. + PAUL F. LIZZUL, M.D., PH.D., M.P.H, M.B.A. Chief Medical Officer Dr. Lizzul joined AnaptysBio in July 2020 and leads the company’s development organization, including clinical medicine, clinical operations, regulatory affairs, pharmacology and toxicology functions. + ERIC LOUMEAU Chief Operating Officer Eric Loumeau joined AnaptysBio in August 2018 with more than twenty years of experience in biotech. + DENNIS MULROY Chief Financial Officer Dennis Mulroy joined AnaptysBio in July 2020 after serving as Chief Financial Officer of La Jolla Pharmaceutical Company + MARGARET (PEGGY) MARINO, PH.D. Senior Vice President, Project Management Margaret Marino, Ph.D., joined AnaptysBio from Pfizer, where she was responsible for external R&D innovation and project management across a number of biologics programs within the CovX Biotech Unit. + BETH MUELLER Senior Vice President, Human Resources Beth Mueller joined AnaptysBio in October 2019 with over 20 years of experience in all aspects of human resources, including organizational development, talent acquisition, and compensation in the biotechnology industry. + MARTIN DAHL, PH.D. Vice President, Discovery Biology Martin Dahl, Ph.D. joined AnaptysBio in 2018 and has more than 25 years of experience in drug discovery and research. + STEPHEN PARMLEY, PH.D. Vice President, Target Biology Stephen Parmley joined AnaptysBio in November of 2015 with more than 30 years of experience in protein engineering, immunology and project leadership. + BOARD OF DIRECTORS JAMES N. TOPPER, M.D., PH.D. Chairman of AnaptysBio Managing General Partner at Frazier Healthcare Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies. + HOLLINGS RENTON Former President and CEO of Onyx Pharmaceuticals Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008. + JOHN SCHMID Former CFO of Auspex Pharmaceuticals John Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to Auspex, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013. + DENNIS FENTON, PH.D. Former Executive Vice President, Amgen Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President. + J. ANTHONY WARE, M.D. Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and Company Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas. + LAURA J. HAMILL Former Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences Laura J. Hamill joined our Board of Directors in September 2019. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. + MAGDA MARQUET, PH.D. Co-founder of Althea Technologies, AltheaDx and ALMA Life Sciences, LLC Dr. Magda Marquet joined our Board of Directors in January 2021. She was the co-CEO of Althea Technologies from 2000 to 2008. She is currently the co-CEO of Alma Life Sciences. LLC, an investment and consulting firm and serves on several Boards of Directors. + OLEG NODELMAN Founder and Portfolio Manager of EcoR1 Capital LLC Oleg Nodelman joined our Board of Directors in April 2021. He is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, and has nearly twenty years of experience in biotech investing. + HAMZA SURIA President and CEO, AnaptysBio, Inc. Hamza Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas. + RESEARCH AND DEVELOPMENT COMMITTEE MICHAEL GALLATIN, PH.D. Former Vice President and Scientific Director of ICOS Corporation Michael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®). + CHRISTOPHER HUNTER, PH.D. Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine Christopher Hunter, Ph.D. is the Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine. Dr. Hunter’s research has focused on the host’s immune response to infections and the innate events that lead to the development of long term protective immunity mediated […] + JOHN G. MONROE, PH.D. Emeritus Professor, University of Pennsylvania School of Medicine John G. Monroe, Ph.D., is an Emeritus Professor at the Perelman School of Medicine at the University of Pennsylvania. He is a former Senior Director at Genentech where he led the Immunology Discovery Department that is responsible for new target discovery and pre-clinical validation. + DENNIS FENTON, PH.D. Former Executive Vice President, Amgen Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President. + JAMES N. TOPPER, M.D., PH.D. Chairman of AnaptysBio Managing General Partner at Frazier Healthcare Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies. + J. ANTHONY WARE, M.D. Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and Company Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas. + CONTACT AnaptysBio, Inc. 10770 Wateridge Circle Suite 210 San Diego, CA 92121-5801 Phone: (858) 362-6295 Fax: (858) 362-6296 info@anaptysbio.com General Information info@anaptysbio.com Job Opportunities Please see our Job Openings page. ABOUT Overview Strategy Management Board of Directors Research and Development Committee Contact TECHNOLOGY Therapeutic Antibodies Somatic Hypermutation SHM Platform Key Advantages Publications PIPELINE Overview Imsidolimab Rosnilimab ANB032 Partnerships INVESTORS / NEWS Overview News Events Goverance Stock Information Analyst Coverage SEC Filings FAQs Contact CAREERS Overview Job Openings Health and Financial Benefits Overview CONNECT LinkedIn Twitter CONTACT Phone: (858)362-6295 info@anaptysbio.com © 2021 ANAPTYSBIO, INC. ALL RIGHTS RESERVED. PRIVACY POLICY | TERMS OF USE